Feedback / Questions
etrolizumab (RG7413) - Roche
Etrolizumab: Data from P3 BERGAMOT trial (NCT02394028) for moderate-to-severe Crohn's disease in 2021
(Roche, Barclays Global Healthcare Conference 2020)
Mar 13, 2020
P3 data
https://www.roche.com/dam/jcr:8136122c-d7cd-4162-b658-fd16abd43fb7/en/barclays-presentation-march-2020.pdf
Mar 13, 2020
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious